Celgene gains on Revlimid data
Shares of Celgene Corp. (NASDAQ:CELG) added $9.84 to $134.92 on Thursday after the company said continuous oral Revlimid lenalidomide plus low-dose dexamethasone until disease progression met the primary endpoint in the Phase III FIRST (MM-020/IFM 07-01) trial to treat newly diagnosed multiple myeloma (MM). Revlimid plus dexamethasone significantly improved progression-free survival (PFS) vs. a combination of melphalan, prednisone and thalidomide. The open-label, international trial enrolled 1,623 patients with newly diagnosed MM who were ineligible for autologous stem cell transplantation (ASCT). Celgene said it plans to submit regulatory applications in the U.S., EU and other countries for Revlimid in newly diagnosed MM starting in 4Q13. ...